"Receptors, Prolactin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Labile proteins on or in prolactin-sensitive cells that bind prolactin initiating the cells' physiological response to that hormone. Mammary casein synthesis is one of the responses. The receptors are also found in placenta, liver, testes, kidneys, ovaries, and other organs and bind and respond to certain other hormones and their analogs and antagonists. This receptor is related to the growth hormone receptor.
| Descriptor ID |
D011981
|
| MeSH Number(s) |
D12.776.543.750.720.600.710 D12.776.543.750.750.555.710 D12.776.543.750.750.660.350.725
|
| Concept/Terms |
Receptors, Prolactin- Receptors, Prolactin
- Prolactin Receptors
- Receptors, PRL
- PRL Receptors
- Prolactin Receptor
- Receptor, Prolactin
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Prolactin".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Neuropeptide [D12.776.543.750.720.600]
- Receptors, Prolactin [D12.776.543.750.720.600.710]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Neuropeptide [D12.776.543.750.750.555]
- Receptors, Prolactin [D12.776.543.750.750.555.710]
- Receptors, Pituitary Hormone [D12.776.543.750.750.660]
- Receptors, Gonadotropin [D12.776.543.750.750.660.350]
- Receptors, Prolactin [D12.776.543.750.750.660.350.725]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Prolactin".
This graph shows the total number of publications written about "Receptors, Prolactin" by people in this website by year, and whether "Receptors, Prolactin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Prolactin" by people in Profiles.
-
Popnikolov N, Brzezinska K, Platoff RM, Binnebose R, Rothstein-Rubin R, Komarnicky LT, Woodworth A. Upregulation of Prolactin Receptor Expression and Activation of Prolactin Signaling in an Aggressive Triple-Negative Breast Carcinoma During Pregnancy: A Case Report. Clin Breast Cancer. 2020 10; 20(5):e529-e539.
-
Liu Y, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers. Mol Endocrinol. 2016 May; 30(5):504-17.
-
Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs SY, Frank SJ. The role of prolactin receptor in GH signaling in breast cancer cells. Mol Endocrinol. 2013 Feb; 27(2):266-79.
-
Xu C, Langenheim JF, Chen WY. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):157-69.
-
Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, Chen WY, Frank SJ. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol Endocrinol. 2011 Apr; 25(4):597-610.
-
Tomblyn S, Springs AE, Langenheim JF, Chen WY. Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice. Int J Oncol. 2009 Apr; 34(4):1139-46.
-
Langenheim JF, Chen WY. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor. J Recept Signal Transduct Res. 2009; 29(2):107-12.
-
Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2008 Sep; 111(2):241-50.
-
Langenheim JF, Tan D, Walker AM, Chen WY. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. Mol Endocrinol. 2006 Mar; 20(3):661-74.
-
Langenheim JF, Chen WY. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A. Breast Cancer Res Treat. 2005 Apr; 90(3):281-93.